Figure 5. IRF4 Expression Is Critical for the Presence of PDL2⁺ CD301b⁺ DCs in Skin dLNs.

(A) IRF4 protein expression in PDL2⁺ skin dLN DCs were examined by flow cytometry.

(B) MHCII^hi CD11c⁺ DCs from skin dLNs of WT and Irf4^flox/floxxCd11c-cre mice were examined by flow cytometry for PDL2, CD301b, CD103, and EpCAM expression. The percentages of PDL2⁺ CD301b⁺ and PDL2⁺ CD301b⁻ DCs (left), dermal CD103⁺ DCs (middle), and EpCAM⁺ Langerhans cells (right) were shown as indicated. Data are representative of three independent experiments.

(C) Percentages of PDL2⁺ CD301b⁺ DCs in the skin dLNs of WT and Irf4^flox/floxxCd11c-cre mice. Data are represented as mean ± SD. **p < 0.01.

(D) Percentages of PDL2⁺ CD301b⁺ DCs in the ear dermis of WT and Irf4^flox/floxxCd11c-cre mice. Data are represented as mean ± SD.